A5065697279- Organ Transplantation Techniques and Outcomes
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Mesenchymal stem cell research
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- MicroRNA in disease regulation
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- Chemokine receptors and signaling
- Lung Cancer Research Studies
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Management of metastatic bone disease
- Immune cells in cancer
- Renal Transplantation Outcomes and Treatments
- Circular RNAs in diseases
- Lung Cancer Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Pain Management and Opioid Use
- interferon and immune responses
- Colorectal Cancer Screening and Detection
- Cytokine Signaling Pathways and Interactions
Southeast University
2024-2025
Nanjing Medical University
2012-2024
Nanjing General Hospital of Nanjing Military Command
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2023
Jiangsu Province Hospital
2009-2023
State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation
2022
Modular Genetics (United States)
2022
Objective This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. Methods Initially, 20 HCC were screened 18 enrolled this open-label, single-arm, phase II clinical trial. Patients received three cycles therapy including doses concurrent for 21 days followed by surgery. Four 8 weeks after surgery, eight adjuvant combination apatinib. Major pathological reactions (MPR), complete (pCR),...
It has been previously reported that IL-22, one of the cytokines secreted by Th17 cells, demonstrates both a protective and inflammatory promotion effect in bowel disease (IBD) through STAT3 signaling activation. We sought to investigate role IL-22 expression colon cancer (CC).The related molecules were detected human CC, detail function mechanism investigated vivo vitro model.Our results demonstrated significant upregulation CC tumor infiltrated leukocytes (TILs) compared peripheral...
Ischemia-reperfusion (I/R) associated with small-for-size liver transplantation (SFSLT) impairs graft regeneration. Mesenchymal stem cells (MSCs) have the capability, under specific conditions, of differentiating into hepatocytes. Hepatocyte growth factor (HGF) has potent anti-apoptotic and mitogenic effects on hepatocytes during injury, been utilized in many experimental clinical applications. In this study, we implanted HGF-expressing MSCs grafts via portal vein, using a 30% rat model....
Ischemia-reperfusion and chronic injuries associated with small-for-size liver transplantation (SFSLT) impair the regeneration of graft induce fibrosis. Mesenchymal stem cells (MSCs) can prevent development fibrosis, hepatocyte growth factor (HGF) also attenuate cirrhosis. Our previous studies have demonstrated that higher occurrence fibrosis existed in rats post-SFSLT, implantation HGF/MSCs, human HGF (hHGF)-expressing MSCs, improve regeneration, reduce mortality rats, as well potent...
We conducted a multicenter, partially randomized, platform trial to assess the effectiveness of booster dose an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in Chinese adults (NCT05855408). Between May 23, 2023, and August 28, 4089 eligible participants were equally randomized receive either Ad5-nCoV via oral inhalation at 0.1 mL (IH Ad5-nCoV, n = 2039) injection 0.5 (IM 2050). Additionally, 2008 who declined but consented participate surveillance...
Abstract Mesenchymal stem cells (MSCs) possess the ability to migrate toward tumor sites and are regarded as promising gene delivery vehicles for cancer therapeutics. However, factors that mediate this tropism have yet be completely elucidated. In study, through cytokine array analysis, chemokine CCL15 was found most abundant protein differentially expressed in hepatocellular carcinoma (HCC) cell lines compared with a normal liver line. Serum levels HCC patients determined by enzyme linked...
A microarray-based high-throughput screening of human circulating circular RNA (circRNA) was applied with five patients newly diagnosed hepatocellular carcinoma (HCC), HBV-positive chronic hepatitis (CH) and healthy controls (NC) enrolled. The plasma HCC after hepatectomy also collected. After multiple staged validation, we obtained circRNAs as candidate. Based on the stratified risk score analysis, three increased including circ_0009582, circ_0037120 circ_0140117 were confirmed candidate...
Acute rejection is commonly encountered for long-term survival in liver transplant (LT) recipients and may impact their if severe or recurrent. The aim of this study to examine the therapeutic potential transforming growth factor (TGF-β)-overexpressing mesenchymal stem cells (MSCs) inducing a local immunosuppression grafts after transplantation. MSCs were transduced with lentiviral vector expressing human TGF-β1 gene; TGF-β1-overexpressing (designated as TGF/MSCs) then transfused into via...
Never in mitosis gene A‑related kinase (Nek) 6 is a recently identified Nek that required for mitotic cell cycle progression; however, the role and mechanism of Nek6 activity during hepatocarcinogenesis not well known. The aim this study was to investigate potential roles internal hepatocellular carcinoma (HCC) development. In present study, found be overexpressed HCC samples lines by florescent real‑time quantitative polymerase chain reaction, immunohistochemistry western blot analysis....
•A total of 21 patients (14 hepatocellular carcinoma and 7 cholangiocarcinoma) were enrolled in this study.•Twelve had AEs.•The objective remission rate ascites was 43.75%.•The median OS for all 17.6 weeks. BackgroundAdvanced primary liver cancer with malignant have a poor prognosis lack effective treatment plans. This phase Ib study aims to explore the safety clinical efficacy intraperitoneal anti-programmed cell death protein 1 (PD-1) antibody these patients.Patients methodsPatients...
Background Small-for-size syndrome (SFSS) may occur when graft volume is less than 45% of the standard liver volume, and it manifests as retarded growth failure grafts more mortality. However, its pathogenesis poorly understood, few effective interventions have been attempted. Aims The present study aimed to delineate critical role oxidant stress in SFSS protective effects a superoxide dismutase mimetic, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), on function, growth,...
Background: Despite the emergence of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced hepatocellular carcinoma (HCC), there is an unmet need regarding subsequent treatments in patients that fail ICI. Regorafenib a vascular endothelial growth factor receptor (VEGFR) inhibitor, which could increase programmed death-ligand 1 (PD-L1) expression tumors and intra-tumoral CD8+ T-cell infiltration by normalizing cancer vasculature improving efficacy cell death protein (PD-1)...
In this study, adenovirus carrying human HGF gene (Ad-HGF) was administered to investigate whether hepatocyte growth factor (HGF) can restore liver regeneration after prolonged cold ischemia, especially during the initiation phase, in a rat model of small-for-size transplantation.A established using 30% grafts. Before hand, grafts were preserved at 4°C for 45min, 2h, 6h and 10h UW solution. A recombinant adenoviral vector Ad-HGF or encoding enhanced green fluorescent protein (Ad-EGFP) group....
e16146 Background: The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted TKIs, such lenvatinib sorafenib, are approved for 1st-line Sintilimab, a novel selective anti-PD-1 monoclonal antibody, demonstrated encouraging clinical activities trial aims to explore the safety efficacy sintilimab plus anlotinib (a TKI against angiogenesis) Methods: This is single-arm phase 2 study. Eligible Pts with aHCC, BCLC...
Heterologous booster vaccines are more effective than homologous in combating the coronavirus disease 2019 (COVID-19) outbreak. However, our understanding of and heterologous for COVID-19 remains limited.